Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
The Netherlands Journal of Medicine
|
September 29, 2017
Health promotion and disease prevention can substantially reduce the total economic burden of diabetes in the Netherlands
J A M J L Janssen
The Netherlands Journal of Medicine
|
November 20, 2015
Continuous intraperitoneal insulin infusion (CIPII) for type 1 diabetes: Effective therapy but a case of bad timing?
J A M J L Janssen
Reviews in Endocrine & Metabolic Disorders
|
July 8, 2008
Advantages and disadvantages of GH/IGF-I combination treatment
J A M J L Janssen
Hormone Research in Paediatrics
|
July 23, 2011
Insulin-like growth factor I: pros and cons of a bioassay
J A M J L Janssen
Hormone Research
|
November 13, 2004
Igf-I and longevity
J A M J L Janssen, S W J Lamberts
European Journal of Endocrinology
|
March 28, 2002
The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?
J A M J L Janssen, S W J Lamberts
Nederlands Tijdschrift Voor Geneeskunde
|
June 1, 2002
[Hepatocellular carcinoma complicated by non-islet cell tumor hypoglycemia]
P van Wijngaarden, J A M J L Janssen, R A de Man
Nederlands Tijdschrift Voor Geneeskunde
|
October 16, 2004
[Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe]
J A M J L Janssen, W E Visser, A J van der Lely
Journal of Endocrinological Investigation
|
July 6, 2004
Is there a role of ghrelin in preventing catabolism?
J A M J L Janssen, A J van der Lely, S W J Lamberts
Journal of Endocrinological Investigation
|
September 4, 2003
Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity
J A M J L Janssen, A J van der Lely, S W J Lamberts
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
The Netherlands Journal of Medicine
|
September 29, 2017
Health promotion and disease prevention can substantially reduce the total economic burden of diabetes in the Netherlands
J A M J L Janssen
The Netherlands Journal of Medicine
|
November 20, 2015
Continuous intraperitoneal insulin infusion (CIPII) for type 1 diabetes: Effective therapy but a case of bad timing?
J A M J L Janssen
Reviews in Endocrine & Metabolic Disorders
|
July 8, 2008
Advantages and disadvantages of GH/IGF-I combination treatment
J A M J L Janssen
Hormone Research in Paediatrics
|
July 23, 2011
Insulin-like growth factor I: pros and cons of a bioassay
J A M J L Janssen
Hormone Research
|
November 13, 2004
Igf-I and longevity
J A M J L Janssen, S W J Lamberts
European Journal of Endocrinology
|
March 28, 2002
The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?
J A M J L Janssen, S W J Lamberts
Nederlands Tijdschrift Voor Geneeskunde
|
June 1, 2002
[Hepatocellular carcinoma complicated by non-islet cell tumor hypoglycemia]
P van Wijngaarden, J A M J L Janssen, R A de Man
Nederlands Tijdschrift Voor Geneeskunde
|
October 16, 2004
[Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe]
J A M J L Janssen, W E Visser, A J van der Lely
Journal of Endocrinological Investigation
|
July 6, 2004
Is there a role of ghrelin in preventing catabolism?
J A M J L Janssen, A J van der Lely, S W J Lamberts
Journal of Endocrinological Investigation
|
September 4, 2003
Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity
J A M J L Janssen, A J van der Lely, S W J Lamberts
Page
of 4